Ash Biomedical Diagnostics Ltd, an indigenous Nigerian healthcare company, has announced the production of seven rapid diagnostic products for HIV, malaria, hepatitis, and pregnancy testing. The company's Managing Director, Adetoyese Shodeinde, disclosed this in a statement on Monday, September 21, 2026. The seven products, comprising 12 Stock Keeping Units (SKUs), cover four key healthcare testing areas. This development is a step forward for locally developed diagnostic solutions in Nigeria.
The seven products launched by Ash Biomedical Diagnostics Ltd are ABD HIVChek, MalChek, MalChek Plus, HepaQuik, HepaQuik Duo, PregSure, and FlaviQuik. These products support healthcare providers and screening programs in identifying people who may require further medical evaluation during a single patient encounter. According to Shodeinde, the development represents progress towards strengthening confidence in locally developed healthcare solutions and expanding access to rapid diagnostic tools that can support earlier disease detection.
Two of the products, FlaviQuik and HepaQuik Duo, are designed for rapid Hepatitis C testing and dual screening for Hepatitis B and C, respectively. These products are now available across the country. Shodeinde said the achievement followed years of investment in quality, regulatory compliance, and product development. The company's vision is to build confidence in Nigerian healthcare manufacturing by ensuring that every product meets the standards required for quality, reliability, and national regulatory approval.
Ash Biomedical Diagnostics Ltd has made significant progress in expanding access to rapid diagnostic tools. The company's growing hepatitis portfolio complements its broader commitment to developing practical diagnostic solutions that make quality testing more accessible across Nigeria. Shodeinde emphasized that the company's expanded hepatitis portfolio arrives as increased hepatitis screening continues to draw national and global attention.
The company's products have reached all 36 states of Nigeria, and it has delivered 15 million test kits over 15 years through more than 66 government and institutional contracts across 27 states. Shodeinde said that Ash Biomedical's vision has always been bigger than producing diagnostic kits. The company aims to contribute additional rapid diagnostic options that support healthcare professionals in screening patients more efficiently.
HepaQuik Duo enables dual screening for Hepatitis B and Hepatitis C using one test, supporting healthcare providers and screening programs in identifying individuals who may require further medical evaluation during a single patient encounter. This development is expected to support earlier disease detection and strengthen confidence in locally developed healthcare solutions.
The launch of these seven rapid diagnostic products is a significant milestone for Ash Biomedical Diagnostics Ltd. The company's commitment to developing practical diagnostic solutions that make quality testing more accessible across Nigeria is commendable. With its expanded hepatitis portfolio, Ash Biomedical is contributing to the national and global attention on increased hepatitis screening.
Key points
- Ash Biomedical Diagnostics Ltd launches seven rapid diagnostic products for HIV, malaria, hepatitis, and pregnancy testing.
- The products support healthcare providers and screening programs in identifying people who may require further medical evaluation during a single patient encounter.
- The company has delivered 15 million test kits over 15 years through more than 66 government and institutional contracts across 27 states.
